Free Trial
ASX:DNK

Danakali (DNK) Stock Price, News & Analysis

About Danakali Stock (ASX:DNK)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
A$151.02 million
P/E Ratio
107.77
Dividend Yield
4.88%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danakali and its competitors with MarketBeat's FREE daily newsletter.

DNK Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

DNK Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Danakali investors own include Knowles (KN), Aurinia Pharmaceuticals (AUPH), Athenex (ATNX), Ascendis Pharma A/S (ASND), Ardelyx (ARDX), Arcturus Therapeutics (ARCT) and Aptose Biosciences (APTO).

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Agricultural Inputs
Sub-Industry
Real Estate
Current Symbol
ASX:DNK
CIK
N/A
Fax
N/A
Employees
5,205
Year Founded
N/A

Profitability

Trailing P/E Ratio
107.77
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
A$1.52 million
Net Margins
377,693.53%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
A$0.11 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
A$151.02 million
Optionable
Not Optionable
Beta
0.73
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (ASX:DNK) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners